Individualized homeopathy added to treatment for stage IV lung cancer

MS-N146 · Cancer control and quality of life · Contested trial · Retraction history · Human evidence · Appraised 26 October 2026

Does individualized add-on homeopathy improve quality of life or survival in stage IV non-small-cell lung cancer?

Evidence at a glance

Evidence label: A positive randomized report exists, but it republishes a contested dataset whose earlier paper was retracted; independent confirmation is absent
Benefit: The 2026 paper reports better quality of life and longer survival, but the reliability and independence of that finding are unresolved.
Certainty: Very low because this is the same NCT01509612 dataset as the retracted 2020 article, not a new replication, and the survival result is unusually large.
Risk: Highly diluted products may have little direct toxicity, but mislabeled products, alcohol or active ingredients, cost and delayed effective treatment remain concerns.

What was studied

Design and population: NCT01509612 enrolled 150 people with advanced non-small-cell lung cancer receiving conventional oncology care. Ninety-eight were randomized and blinded to individualized homeopathic products (n=51) or placebo globules (n=47); 52 who declined randomization formed a non-randomized observation group. Quality of life was assessed at 9 and 18 weeks; survival was followed for 730 days.

Publication history: The dataset was published in The Oncologist in 2020, received an expression of concern and corrections, and was retracted in November 2025 because the journal no longer had confidence in its results and conclusions. A Supportive Care in Cancer article published 10 September 2026 reanalyzed and republished the same trial dataset. It is therefore not independent replication despite “replicate” language in its aim.

What the evidence found

The 2026 article reports higher EORTC QLQ-C30 global health status with homeopathy than placebo at 9 and 18 weeks (P<.001). Reported median survival was 435 days versus 257 days (P=.010), and 2-year survival 45.1% versus 23.4% (P=.020). The non-randomized group had median survival 228 days.

ClinicalTrials.gov lists 150 actual participants and results posted in 2020. Because the 2026 paper uses those same participants and outcomes, it does not resolve the need for a new, independently run trial.

Broader systematic reviews of homeopathy in oncology have found heterogeneous and insufficient evidence. A few product-specific supportive-care trials cannot establish cancer control by homeopathy as a system.

How to interpret it

The reported survival difference is a signal requiring independent verification, not a basis for a cure claim. Retraction history, same-dataset republication, changes in reporting and affiliations with homeopathy organizations all need transparent consideration.

Homeopathy must not replace immunotherapy, targeted therapy, chemotherapy, radiotherapy, surgery or palliative care. Any symptom benefit should be evaluated separately from tumor response and survival.

Practical safety context

Bring the exact product and dilution to the oncology pharmacist; some products labeled homeopathic contain measurable ingredients or alcohol. The largest practical risk is displacement or delay of effective care. New symptoms should not be dismissed as a “homeopathic aggravation.”

Questions for the care team

Is the cited paper a genuinely new trial, or a reanalysis of NCT01509612?
How does the clinician account for the 2025 retraction and the lack of independent replication?
Will standard cancer treatment, imaging and symptom management continue without delay?

Funding and conflicts

The 2026 paper states support from the Institute for Homeopathic Research, Vienna (grant 0112). Several authors list affiliations with homeopathy research or professional organizations. The prior article from the same dataset was retracted; most authors disagreed with that decision. These facts do not by themselves prove the result false, but they materially lower confidence until independent replication.

Sources

Last literature search: 26 October 2026. Record appraisal: 26 October 2026. This page is educational and does not replace individualized medical advice. Laboratory effects, biomarkers, symptom changes or an uncontrolled response must not be interpreted as proof of tumor control, delayed recurrence or longer survival.